Replies to post #122192 on Biotech Values

[biomaven0]

management has not openly acknowledged that the program is dead

From their latest 10-K

Overview
We are a biotechnology company focused on the development of small-molecule therapeutics for the
treatment of serious diseases. We have the following product candidates in development, including:
• Lesinurad (previously called RDEA594): An inhibitor of the URAT1 kidney transporter for the
treatment of hyperuricemia and gout;
• Next-generation URAT1 inhibitors: Next generation URAT1 kidney transporter inhibitors for the
treatment of hyperuricemia and gout; and
• BAY 86-9766 (formerly known as RDEA119): A MEK inhibitor for the treatment of cancer.

So not even listed as products in development. Their website says something to effect that any further development will depend on partnering.

So somewhere between dead and 3 on the Glasgow coma scale. :)

Peter